Analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to announce $43.40 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings. The highest sales estimate is $44.70 million and the lowest is $42.00 million. Vanda Pharmaceuticals reported sales of $37.42 million during the same quarter last year, which indicates a positive year over year growth rate of 16%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $43.40 million for the current fiscal year, with estimates ranging from $190.60 million to $193.80 million. For the next financial year, analysts anticipate that the firm will report sales of $237.67 million per share, with estimates ranging from $223.00 million to $262.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44.00 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. Vanda Pharmaceuticals’s revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 earnings per share.
In related news, SVP Gunther Birznieks sold 8,568 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total transaction of $130,747.68. Following the completion of the sale, the senior vice president now owns 118,366 shares in the company, valued at $1,806,265.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Patrick Kelly sold 8,532 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total value of $159,719.04. Following the sale, the chief financial officer now owns 208,066 shares of the company’s stock, valued at approximately $3,894,995.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 287,506 shares of company stock valued at $4,665,795. Company insiders own 7.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in VNDA. Northern Trust Corp grew its position in shares of Vanda Pharmaceuticals by 16.5% during the second quarter. Northern Trust Corp now owns 597,928 shares of the biopharmaceutical company’s stock worth $9,747,000 after purchasing an additional 84,834 shares in the last quarter. California Public Employees Retirement System grew its position in shares of Vanda Pharmaceuticals by 3.8% during the second quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 2,200 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in shares of Vanda Pharmaceuticals by 52.9% during the second quarter. Parametric Portfolio Associates LLC now owns 36,919 shares of the biopharmaceutical company’s stock worth $602,000 after purchasing an additional 12,769 shares in the last quarter. Voya Investment Management LLC grew its position in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares in the last quarter. Finally, State Street Corp grew its position in shares of Vanda Pharmaceuticals by 2.9% during the second quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock worth $26,380,000 after purchasing an additional 46,299 shares in the last quarter. Hedge funds and other institutional investors own 89.96% of the company’s stock.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) traded up $0.05 on Wednesday, reaching $19.95. The company’s stock had a trading volume of 384,562 shares, compared to its average volume of 632,471. The stock has a market capitalization of $894.06, a PE ratio of -57.00 and a beta of 1.02. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $20.05.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.